Copeland Susan E, Ladd Leigh A, Gu Xiao-Qing, Mather Laurence E
Department of Anaesthesia and Pain Management, University of Sydney at Royal North Shore Hospital, Sydney NSW 2065, Australia.
Anesth Analg. 2008 May;106(5):1440-9, table of contents. doi: 10.1213/ane.0b013e31816ba541.
Local anesthetic toxicity is often studied experimentally in anesthetized subjects, but clinical toxicity usually occurs in conscious patients. In this study, we determined the influence of general anesthesia on the pharmacokinetics of six local anesthetics administered i.v. at approximately the highest recommended doses.
Chronically instrumented ewes (approximately 45-50 kg, n = 18) were infused over 3 min with (base doses as HCl salts) bupivacaine (100 mg), levobupivacaine (125 mg), ropivacaine (150 mg), lidocaine (350 mg), mepivacaine (350 mg), or prilocaine (350 mg), on separate occasions when conscious and halothane anesthetized. Serial arterial, heart, and brain venous blood drug concentrations were measured by achiral/chiral high-performance liquid chromatography, as relevant. Whole body pharmacokinetics were assessed by noncompartmental analysis; heart and brain pharmacokinetics were assessed by mass balance. Drug blood binding, in the absence and presence of halothane, was assessed by equilibrium dialysis in vitro.
Blood local anesthetic concentrations were doubled with anesthesia because of decreased whole body distribution and clearance (respectively, to 33% and 52% of values when conscious). Heart and brain net drug uptake were greater under anesthesia, reflecting slower efflux from both regions. Clearances of R-bupivacaine > S-bupivacaine and R-prilocaine > S-prilocaine, but, mepivacaine clearance was not enantioselective. Halothane did not influence blood binding of the local anesthetics.
General anesthesia significantly changed whole body and regional pharmacokinetics of each local anesthetic as well as the systemic effects. General anesthesia is thus an important but frequently overlooked factor in studies of local anesthetic toxicity.
局部麻醉药毒性通常在麻醉状态的受试者身上进行实验研究,但临床毒性通常发生在清醒患者身上。在本研究中,我们确定了全身麻醉对以大约最高推荐剂量静脉注射的六种局部麻醉药药代动力学的影响。
对18只长期植入仪器的母羊(体重约45 - 50千克),在清醒和氟烷麻醉状态下分别进行3分钟的静脉输注(以盐酸盐形式的基础剂量),分别给予布比卡因(100毫克)、左旋布比卡因(125毫克)、罗哌卡因(150毫克)、利多卡因(350毫克)、甲哌卡因(350毫克)或丙胺卡因(350毫克)。根据需要,通过非手性/手性高效液相色谱法测定系列动脉血、心脏和脑静脉血中的药物浓度。通过非房室分析评估全身药代动力学;通过质量平衡评估心脏和脑药代动力学。在有和没有氟烷存在的情况下,通过体外平衡透析评估药物与血液的结合。
由于全身分布和清除率降低(分别降至清醒时数值的33%和52%),麻醉状态下血液中局部麻醉药浓度加倍。麻醉状态下心脏和脑的药物净摄取量更大,这反映了药物从这两个区域的流出更慢。R-布比卡因的清除率 > S-布比卡因,R-丙胺卡因的清除率 > S-丙胺卡因,但甲哌卡因的清除率没有对映体选择性。氟烷不影响局部麻醉药与血液的结合。
全身麻醉显著改变了每种局部麻醉药的全身和区域药代动力学以及全身效应。因此,全身麻醉是局部麻醉药毒性研究中一个重要但经常被忽视的因素。